Company
BioNTech
BioNTech has 36 drugs tracked on RxWires: 1 post-market, 6 in Phase 3, 2 in Phase 2/3, 3 in Phase 2, 12 in Phase 1/2, 12 in Phase 1.
- Ticker
- BNTX
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| BNT162b2 Vaccine | Post-Market | COVID-19 Vaccines |
| BNT323/DB-1303 | Phase 3 | Endometrial Cancer |
| Pumitamig | Phase 3 | Breast Neoplasms |
| BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | Phase 3 | COVID-19 |
| PM8002 | Phase 3 | Triple Negative Breast Cancer(TNBC) |
| BNT324 | Phase 3 | Metastatic Castration-resistant Prostate Cancer |
| Influenza and COVID-19 Combination A | Phase 3 | Influenza |
| BNT162b1 | Phase 2/3 | SARS-CoV-2 Infection |
| BNT113 | Phase 2/3 | Unresectable Head and Neck Squamous Cell Carcinoma |
| RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II |
| BNT327 Dose Level 1 (DL1) | Phase 2 | Extensive-stage Small-cell Lung Cancer |
| DB-1311/BNT324 | Phase 2 | Solid Tumors |
| BNT323 | Phase 1/2 | Locally Advanced Breast Cancer |
| DB-1305/BNT325 | Phase 1/2 | Advanced Solid Tumor |
| BNT3210 | Phase 1/2 | Advanced Solid Tumors |
| BNT326 | Phase 1/2 | Non-small Cell Lung Cancer |
| Investigational Influenza Vaccine | Phase 1/2 | Influenza,Human |
| BNT329 | Phase 1/2 | Advanced Solid Cancers |
| PM1032 injection | Phase 1/2 | Advanced Tumor |
| BNT142 | Phase 1/2 | Solid Tumor |
| BNT151 | Phase 1/2 | Solid Tumor |
| PM1003 Injection | Phase 1/2 | Advanced Solid Tumors |
| BNT411 | Phase 1/2 | Solid Tumor |
| DB-1311 | Phase 1/2 | Advanced Solid Tumors |
| MVT-2163 | Phase 1 | Pancreatic Carcinoma |
| BNT165b1 | Phase 1 | Malaria |
| BNT331 | Phase 1 | Bacterial Vaginosis |
| IVAC_W_bre1_uID | Phase 1 | Breast Cancer (Triple Negative Breast Cancer (TNBC)) |
| CD73 Antigen | Phase 1 | Advanced Solid Tumor |
| BNT152 | Phase 1 | Solid Tumor |
| BNT163 | Phase 1 | Genital Herpes Simplex Type 2 |
| NEO-PV-01 | Phase 1 | Urinary Bladder Cancer |
| Lipo-MERIT | Phase 1 | Melanoma |
| BNT3219 | Phase 1 | Advanced Solid Tumors |
| MVT-5873 | Phase 1 | Pancreatic Cancer |
| APVAC1 vaccine plus Poly-ICLC and GM-CSF | Phase 1 | Glioblastoma |
Latest
Follow BioNTech on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.